Meeting
2012 ASCO Annual Meeting
Multicenter phase II study of concurrent high-dose (72Gy) three-dimensional conformal radiotherapy (3D-CRT) without elective nodal irradiation with chemotherapy using cisplatin and vinorelbine for unresectable stage III non-small cell lung cancer (NSCLC).
Authors
Hidehito Horinouchi
Division of Internal Medicine and Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan
Hidehito Horinouchi , Ikuo Sekine , Minako Sumi , Miyako Satouchi , Hiroshi Isobe , Masao Harada , Seiji Niho , Kiyoshi Mori , Tomohide Tamura
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer - Non-small Cell Local-regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Local-Regional Non–Small Cell Lung Cancer
Clinical Trial Registration Number
UMIN000001743
Citation
J Clin Oncol 30, 2012 (suppl; abstr 7070)
DOI
10.1200/jco.2012.30.15_suppl.7070
Abstract #
7070
Poster Bd #
38E
Abstract Disclosures
Similar Posters
First Author: Hidehito Horinouchi
Poster
2015 ASCO Annual Meeting
A randomized phase II study of TS-1 plus cisplatin versus vinorelbine plus cisplatin with concurrent thoracic radiotherapy for locally advanced non-small cell lung cancer (LA-NSCLC): WJOG 5008L.
First Author: Takashi Seto
Poster
2013 ASCO Annual Meeting
Dose-escalation study of chemoradiotherapy with use of involved-field conformal radiotherapy and accelerated hyperfractionation for stage III non-small cell lung cancer.
First Author: Naruo Yoshimura
Poster
2021 ASCO Annual Meeting
Updated overall survival (OS) and exploratory analysis from the randomized, phase II EVAN study of erlotinib (E) versus vinorelbine plus cisplatin (NP) as adjuvant therapy in Chinese patients with stage IIIA EGFR+ NSCLC.
First Author: Dongsheng Yue